Gastrointestinal cancers in China, the USA, and Europe
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Gastrointestinal (GI) cancers, including colorectal cancer, gastric cancer, and esophageal cancer, are a major medical and economic burden worldwide and have the largest number of new cancer cases and cancer deaths each year. Esophageal and gastric cancers are most common in developing countries, while colorectal cancer forms the major GI malignancy in Western countries. However, a great shift in the predominant GI-cancer type is happening in countries under economically transitioning and, at the same time, esophageal and gastric cancers are reigniting in Western countries due to the higher exposure to certain risk factors. The development of all GI cancers is highly associated with lifestyle habits and all can be detected by identified precancerous diseases. Thus, they are all suitable for cancer screening. Here, we review the epidemiological status of GI cancers in China, the USA, and Europe; the major risk factors and their distribution in these regions; and the current screening strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613 · cited 1×
“Recent studies suggest that waist circumference as a stronger risk factor [38], due to rising evidence on the effects of abdominal/visceral fatness on CRC [39, 40].”
BackgroundGlobal patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Harper, D. M., Kemper, A. R., et al. (2016) · JAMA · doi:10.1001/jama.2016.5989 · Cited by 2,509
Wolf, A. M. D., Fontham, E. T. H., Church, T. R., Flowers, C. R., Guerra, C. E., LaMonte, S. J., Etzioni, R., McKenna, M. T., Oeffinger, K. C., Shih, Y. T., et al. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21457 · Cited by 1,944 · cited 1×
“The incidence and modality of CRC both increase rapidly after the age of 50 years [16, 17].”
BackgroundMultitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · cited 1×
“The FIT-DNA is more sensitive for detecting advanced precancerous lesions and CRC than FIT but has more false-positive results [65].”
BackgroundLevin, B., Lieberman, D. A., McFarland, B., Smith, R. A., Brooks, D., Andrews, K. S., Dash, C., Giardiello, F. M., Glick, S., Levin, T. R., et al. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0018 · Cited by 1,801
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351 · cited 1×
“Aspirin was reported to protect patients from adenoma recurrence and the development of CRC [58, 59].”
Western Diet and the Immune System: An Inflammatory Connection
Christ, A., Lauterbach, M., & Latz, E. (2019) · Immunity · doi:10.1016/j.immuni.2019.09.020 · Cited by 907 · cited 1×
“is also becoming more and prevalent in China [35].”
BackgroundDietary quality among men and women in 187 countries in 1990 and 2010: a systematic assessment
Imamura, F., Micha, R., Khatibzadeh, S., Fahimi, S., Shi, P., Powles, J., & Mozaffarian, D. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(14)70381-x · Cited by 834
Nutrients, foods, and colorectal cancer prevention
Song, M., Garrett, W. S., & Chan, A. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.035 · Cited by 700
Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.36 · Cited by 594 · cited 1×
“Gastric cancer is more common in men than in women (about 2:1) and the most common age at diagnosis is 60 years [72].”
BackgroundEffectiveness of the korean national cancer screening program in reducing gastric cancer mortality
Jun, J. K., Choi, K. S., Lee, H.-Y., Suh, M., Park, B., Song, S. H., Jung, K. W., Lee, C. W., Choi, I. J., Park, E.-C., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.029 · Cited by 570
Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035
Arnold, M., Park, J. Y., Camargo, M. C., Lunet, N., Forman, D., & Soerjomataram, I. (2020) · Gut · doi:10.1136/gutjnl-2019-320234 · Cited by 504 · cited 1×
“In the USA and European countries, gastric cancer is expected to be a rare disease (defined as <6 per 100,000 person-years) by 2035, while the number of new cases will remain high and continue growing [71].”
BackgroundGenetics and Genetic Biomarkers in Sporadic Colorectal Cancer
Carethers, J. M., & Jung, B. H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.047 · Cited by 483 · cited 1×
“CRC is one of the cancers that can benefit most from screening, since the grossly visible lesions usually take 10 years to progress to CRC, leaving a wide time window for early diagnosis [61].”
BackgroundArnold, M., Laversanne, M., Brown, L. M., Devesa, S. S., & Bray, F. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.155 · Cited by 465
Singh, S., Garg, S. K., Singh, P. P., Iyer, P. G., & El-Serag, H. B. (2014) · Gut · doi:10.1136/gutjnl-2013-305997 · Cited by 298
Rezende, L. F. M. D., Sá, T. H. D., Markozannes, G., Rey-López, J. P., Lee, I.-M., Tsilidis, K. K., Ioannidis, J. P. A., & Eluf-Neto, J. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2017-098391 · Cited by 276 · cited 1×
“Physical activity is well known for its potential for reducing cancer risk, but it is only established in colon cancers as an evidential risk factor [42], and the evidence in rectal cancer is not significant.”
BackgroundThe Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites
Anderson, W. F., Rabkin, C. S., Turner, N., Fraumeni, J. F., Rosenberg, P. S., & Camargo, M. C. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx262 · Cited by 270 · cited 1×
“pylori infection [73], which may imply that changes in the prevalence of some lifestyle factors have contributed to the increases shown in more recent generations [74].”
ResultMedication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
Nguyen, D. M., El-Serag, H. B., Henderson, L., Stein, D., Bhattacharyya, A., & Sampliner, R. E. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.001 · Cited by 159 · cited 1×
“The proton-pump inhibitors (PPIs) [153, 154] and NSAID/aspirin [155] have shown protective effects for esophageal cancer.”
Background
Cited by
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
Updated epidemiology of gastrointestinal cancers in East Asia
Huang, J., Lucero-Prisno, D. E., Zhang, L., Xu, W., Wong, S. H., Ng, S. C., & Wong, M. C. S. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00726-3 · Cited by 269
Metadata
- Authors
- Xie, Y., Shi, L., He, X., & Luo, Y.
- Venue
- Gastroenterology Report
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-29
- Volume
- 9
- Issue
- 2
- Pages
- 91-104
- ISSN
- 2052-0034 (ISSN-L)
- OpenAlex
- W3140107099
- Cited by
- 237
- References
- 22
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.